New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 29, 2014
05:46 EDTCELG, BIIBCelgene downgraded to Neutral from Overweight at JPMorgan
JPMorgan downgraded Celgene (CELG) to Neutral saying the company's growth drivers are largely reflected in the stock. JPMorgan finds shares of Biogen (BIIB) more attractive from a pipeline perspective, and it upgraded that stock this morning to Overweight. The firm lowered its price target for Celgene shares to $170 from $180.
News For CELG;BIIB From The Last 14 Days
Check below for free stories on CELG;BIIB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 24, 2014
07:42 EDTCELGCelgene reports Q2 REVLIMID sales increased 15%
Subscribe for More Information
07:34 EDTCELGCelgene raises FY14 adjusted EPS view to $3.60-$3.65 from $3.50-$3.60
Consensus is $3.67. Raises FY14 revenue view to $7.6B from $7.5B, consensus $7.54B. Sees Revlimid net product sales $4.95B from preview $4.9B-$5B range. Sees Abraxane net product sales $850M-$900M.
07:32 EDTCELGCelgene reports Q2 adjusted EPS 90c, consensus 89c
Reports Q2 revenue $1.87B, consensus $1.85B.
06:24 EDTBIIBBiogen price target raised to $387 from $343 at Citigroup
Citigroup raised its price target for Biogen shares to $387 citing the company's earnings and revenue growth following its better than expected Q2 results. Citi keeps a Buy rating on the stock.
July 23, 2014
15:30 EDTCELGNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Ford (F), consensus 36c; General Motors (GM), consensus 58c; Potash (POT), consensus 46c; Caterpillar (CAT), consensus $1.52; 3M (MMM), consensus $1.91; Union Pacific (UNP), consensus $1.43; Bristol-Myers Squibb (BMY), consensus 44c; Eli Lilly (LLY), consensus 65c; Celgene (CELG), consensus 89c; Precision Castparts (PCP), consensus $3.35; Raytheon (RTN), consensus $1.59; Noble Energy (NBL), consensus 79c; Hershey (HSY), consensus 76c; Southwest Airlines (LUV), consensus 61c; Boston Scientific (BSX), consensus 19c; JetBlue (JBLU), consensus 19c.
11:43 EDTBIIBBiogen announces PLEGRIDY EC approval
Subscribe for More Information
10:25 EDTBIIBBiogen price target raised to $420 from $370 at Piper Jaffray
Subscribe for More Information
09:50 EDTBIIBBiogen says strategic bias still tuck-in acquisitions
Subscribe for More Information
09:41 EDTCELGActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL NFLX FB MSFT CELG TWTR TSLA VALE CNW
09:37 EDTBIIBBiogen says 'clearly' has considered tax inversion
Subscribe for More Information
09:25 EDTBIIBBiogen sees Japan as an attractive growth opportunity for company
Says remains committed to SG&A leverage in 2014. Says guidance assumes Tecfidera EU uptake similar to U.S.
09:17 EDTBIIBOn The Fly: Pre-market Movers
Subscribe for More Information
09:05 EDTBIIBBiogen says received letter from EU saying PLEGRIDY has been approved
Subscribe for More Information
08:56 EDTBIIBBiogen still sees FY CapEx approximately $300M
Believes TECFIDERA is on track to become the leading MS product in the U.S. Says outside the U.S., demand for TECFIDERA has been broad; launch trajectories similar to experience in U.S. Continues to be in discussions with AIFA to resolve its dispute on Tysabri for February 2009-January 2013. Says FY guidance "meaningfully increased" due primarily to the  growth  of  TECFIDERA in the U.S. and the EU., the strength of our other MS therapies and clarity on the AIFA pricing matter. Comments from slides that will be presented on the Q2 earnings conference call.
06:50 EDTBIIBBiogen raises FY14 EPS to $12.90-$13.10 from $11.35-$11.45, consensus $11.53
Subscribe for More Information
06:48 EDTBIIBBiogen reports Q2 Tecfidera revenue $700M; Reports Q2 Avonex revenue $774M
Subscribe for More Information
06:47 EDTBIIBBiogen reports Q2 adjusted EPS $3.49, consensus $2.83
Reports Q2 revenue $2.42B, consensus $2.16B; Non-GAAP diluted EPS was benefited by approximately 15c, following the approval from an agreement with the Italian National Medicines Agency relating to Tysabri sales in Italy.
July 22, 2014
14:30 EDTBIIBBiogen technical remarks ahead of earnings
Subscribe for More Information
07:12 EDTCELGCelgene has upper hand in Revlimid case, says Bernstein
Subscribe for More Information
July 21, 2014
07:37 EDTBIIBBiogen July weekly volatility elevated into Q2 and outlook
Biogen July weekly call option implied volatility is at 55, August is at 34, October is at 36; compared to its 26-week average of 33 according to Track Data, suggesting large near term price movement into the expected release of Q2 on July 23.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use